Brendan Connors, OD
Optometrist · Hazle Township, PANPI 1598387102
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 369 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 369 payments — averaging $26.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$2K
- Mallinckrodt Hospital Products Inc.$1K
- Alcon$1K
- Oyster Point Pharma, Inc.$899
- Bausch & Lomb Americas Inc.$626
- Biotissue Holdings Inc.$582
- plus $4K from 21 others
What the payments were for
- Travel & lodging$3253%
- Food & beverage$9,13294%
- Education$2212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 75 | $1,540 |
| Mallinckrodt Hospital Products Inc. | 39 | $1,059 |
| Alcon | 46 | $1,012 |
| Oyster Point Pharma, Inc. | 26 | $899 |
| Bausch & Lomb Americas Inc. | 23 | $626 |
| Biotissue Holdings Inc. | 11 | $582 |
| Dompe US, Inc. | 20 | $568 |
| AbbVie(2 entities) | 22 | $508 |
| Kala Pharmaceuticals, Inc. | 16 | $422 |
| Tarsus Pharmaceuticals, Inc. | 20 | $392 |
| Coopervision Inc. | 8 | $346 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $322 |
| Novartis | 22 | $272 |
| Glaukos Corporation | 3 | $231 |
| Apellis Pharmaceuticals, Inc. | 3 | $155 |
| Rxsight Inc | 1 | $131 |
| LKC Technologies, Inc. | 1 | $121 |
| Amgen(2 entities) | 2 | $88 |
| Optos, Inc. | 1 | $83 |
| Ocular Therapeutix, Inc. | 4 | $71 |
| Quidel Corporation | 1 | $64 |
| Johnson & Johnson Vision Care, Inc. | 3 | $57 |
| Eyevance Pharmaceuticals LLC | 3 | $54 |
| Astellas Pharma US Inc | 1 | $24 |
| Eyepoint US, Inc. | 1 | $19 |
| Harrow Eye, LLC | 1 | $18 |
| Thea Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYRVAYA$376
- Prokera$325
- AmnioGraft$325
- CEQUA$218
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$131
- MIEBO$125
- Syfovre$125
- Oxervate$120
- INFUSE$112
- BIOTRUE$112
- iDose$111
- EYSUVIS$102
- MyDay Contact Lens$102
How this compares
$9,677 in reported general payments places this provider in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 48 | $59,760 |
| LumiganBimatoprost | 92 | $35,210 |
| RestasisCyclosporine | 31 | $31,217 |
| CequaCyclosporine | 34 | $25,645 |
| XiidraLifitegrast | 12 | $22,849 |
| Loteprednol Etabonate | 18 | $5,394 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $2,797 |
| Fluorometholone | 15 | $1,749 |
| Doxycycline Monohydrate | 15 | $726 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 14 | $716 |
| Prednisolone Acetate | 14 | $551 |
| Latanoprost | 20 | $470 |
| Timolol Maleate | 16 | $330 |
| Azithromycin | 13 | $234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $626 | $82,60960 claims |
| AbbVieLumigan, Restasis | $508 | $66,427123 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,540 | $25,64534 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $322 | $5,39418 claims |
| AlconSimbrinza | $1,012 | $2,79712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Other optometrist in Hazle Township
- James DeomHazle Township$793K
- Gregory CaldwellDuncansville$547K
- Leslie O DellNew Freedom$388K
- Kevin BistlinePlymouth Meeting$302K
- Thomas KislanStroudsburg$266K
- Erick HendersonPittsburgh$266K
- Ryan YealyLancaster$164K
- Joseph SmayNew Kensington$147K
- Julie McLaughlinAllentown$142K
- Robert RosenthalNewtown$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.